Cingulate reports Q1 2024 net loss of $3.0M; CTx-1301 NDA filing on track for 1H 2025

Cingulate Inc.

2024-Q1 EPS reported -$0.60

Net loss of $3.0M for Q1 2024, down from $4.0M in Q1 2023.
Cash and equivalents $1.1M as of March 31, 2024, up from $52K at Dec 31, 2023.
Raised $10.7M in capital YTD; $3.3M debt converted to equity by Werth Family.
CTx-1301 NDA filing on track for first half of 2025.
Stockholders' equity improved to $3.2M from ($6.9M) at year-end 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Cingulate Inc. reported for the three months ended March 31, 2024 results: net income Net loss was $3.0 million for the three months ended March 31, 2024, EPS Net loss per share of common stock, basic and diluted $ (0.60 ).

Period: for the three months ended March 31, 2024
Net income: Net loss was $3.0 million for the three months ended March 31, 2024
EPS: Net loss per share of common stock, basic and diluted $ (0.60 )
Result: reported results

Exact text from the filing

On May 8, 2024, Cingulate Inc. issued a press release announcing its financial results for the first quarter of 2024 and providing a clinical and business update.

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

Cingulate Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-018158

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.